- Home
- LENZ vs HURA Comparison
LENZ vs HURA Comparison
Compare LENZ & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LENZ | HURA |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.5M | 160.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LENZ | HURA |
|---|---|---|
| Price | $5.43 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $44.00 | $9.50 |
| AVG Volume (30 Days) | ★ 1.1M | 581.0K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $50.42 | N/A |
| Revenue Next Year | $197.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.68 | $0.41 |
| 52 Week High | $50.19 | $3.90 |
Technical Indicators
Market Signals| Indicator | LENZ | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 40.23 |
| Support Level | $5.23 | $1.82 |
| Resistance Level | $6.21 | $2.20 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 41.83 | 1.00 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.